TriSalus Life Sciences Inc. has announced the initiation of an exchange offer and consent solicitation aimed at streamlining its capital structure by converting outstanding Series A Convertible Preferred Stock into common stock. As part of this initiative, TriSalus is offering holders of the preferred shares the opportunity to exchange their shares for common stock, with the value accrued through dividends considered in the exchange rate. The company plans to issue up to 11,860,206 shares of common stock to complete this conversion process. Additionally, TriSalus seeks approval from preferred shareholders for an amendment that would allow automatic conversion of any remaining preferred shares into common stock post-offer, at a slightly reduced exchange rate. This move is designed to simplify the company's capital layers, reduce dilution, and enhance transparency in ownership. The exchange offer deadline is set for July 23, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.